Soros Fund Management LLC Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB)

Soros Fund Management LLC purchased a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 46,350 shares of the company's stock, valued at approximately $762,000. Soros Fund Management LLC owned approximately 0.09% of Upstream Bio as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. FMR LLC acquired a new stake in Upstream Bio in the 4th quarter worth approximately $117,977,000. Decheng Capital LLC acquired a new stake in shares of Upstream Bio in the fourth quarter worth $54,010,000. TCG Crossover Management LLC bought a new stake in shares of Upstream Bio in the fourth quarter valued at about $44,856,000. Bain Capital Life Sciences Investors LLC acquired a new stake in Upstream Bio during the fourth quarter worth about $37,735,000. Finally, Wellington Management Group LLP acquired a new position in Upstream Bio in the 4th quarter valued at approximately $25,632,000.

Upstream Bio Price Performance

Shares of NASDAQ:UPB traded down $0.23 during trading on Monday, hitting $8.42. 292,470 shares of the stock were exchanged, compared to its average volume of 324,062. Upstream Bio, Inc. has a 1-year low of $5.14 and a 1-year high of $29.46. The company's fifty day simple moving average is $7.96 and its 200-day simple moving average is $14.00.

Upstream Bio Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.